Revolution Medicines, Inc.
RVMD
Clasificación en acciones
#645
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Precio por acción
$178.38
Capitalización bursátil
$38.23B
Cambio (1 día)
0.24%
Cambio (1 año)
229.72%
País
US
Comercio Revolution Medicines, Inc. (RVMD)
Categoría
Healthcare
Margen Operativo de Revolution Medicines, Inc. (RVMD)
Margen Operativo al October 2026 TTM: 0.00%
Según los informes financieros más recientes y el precio de las acciones de Revolution Medicines, Inc., el margen operativo actual (TTM) es 0.00%. Al final de 2023, el margen operativo era -4,207.12%.
Historial de Margen Operativo de Revolution Medicines, Inc. desde 2017 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -4,207.12% | 476.31% |
| 2022 | -730.01% | 14.12% |
| 2021 | -639.70% | 148.39% |
| 2020 | -257.54% | 138.13% |
| 2019 | -108.15% | -45.93% |
| 2018 | -200.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | - |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.